Trial Profile

A Phase IIa, Open-Label, Multi-Center, Multi-Cohort, Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Aug 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary) ; Durvalumab (Primary) ; Gefitinib (Primary) ; Osimertinib (Primary) ; Selumetinib (Primary) ; Tremelimumab (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Sponsors AstraZeneca

22 Jul 2016 Status changed from active, no longer recruiting to completed.
11 Jan 2016 Planned End Date changed from 1 Nov 2017 to 1 Aug 2016 as per ClinicalTrials.gov record.
30 Mar 2015 Status changed from recruiting to active, no longer recruiting, as per ClinicalTrials.gov record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com